Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

Am J HematolJun 29, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)Open access

Teresa Bernal, Javier Zambrano Márquez, Rebeca Rodríguez-Veiga et al.

✦ AI-curated · Sources linked

In 30 seconds

The FLAG-QUIDA trial, a multicenter phase I/II study, evaluated quizartinib combined with FLAG-IDA in adults with relapsed or refractory acute myeloid leukemia (AML). Among 61 patients, the overall complete remission (CR) and CR with incomplete hematologic recovery (CRi) rate was 56%. The median relapse-free survival was significantly improved at 17 months compared to 7.6 months in a matched cohort (p=0.028).

Key findings

  • The recommended phase 2 dose of quizartinib was established at 60 mg/day for 14 days.
  • The overall CR/CRi rate was 56% among patients treated.
  • Median relapse-free survival was 17 months compared to 7.6 months in the matched cohort (p=0.028).
  • Measurable residual disease negativity was achieved in 38% of CR/CRi patients.

Why it matters

This study highlights the potential of quizartinib in combination with FLAG-IDA to improve outcomes in patients with relapsed or refractory AML, particularly in enhancing remission rates and prolonging relapse-free survival.

Source

PubMed · PMID 42374628Free full text on PubMed Central

Published in Am J Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.